Enforced Psychiatric
Treatment: a case study
By Les
Ruthven, Ph.D. Clinical
psychology/health management
Health
blog:
http://www.ruthvenassessments.com/
Email:
lruthven.mafinearts@gmail.com
Charles
Helmer, a 20 year old, was hospitalized at a psychiatric facility with court
approval on an involuntary commitment.
On the unit he was said to be threatening of staff, irritable,
distracted, and easily agitated. I
do not know if this description of his behavior was prior to or following the
court ordered initiation of neuroleptic medications and later enforced
electroconvulsive therapy (ECT).
While in the hospital, and prior to ECT, Charles was placed on Clozaril, Abilify
and Risperdal, all current generation atypical antipsychotic medications.
These 3 medications were said to be partially or not effective.
These 3 medications are FDA approved for schizophrenia, Charles’
diagnosis (schizoaffective schizophrenia was another diagnosis), but such
treatment is off-label or non FDA approved if either of these medications are
used concurrently or serially. I
suspect these medications were used serially because of an inadequate
response to any of these drugs. The
latter is very likely because the experimental drug parade did not stop with
these three drugs. Later court
permission was granted for other enforceable drugs such as Haldol (a 1st
generation antipsychotic), prolixin (a 1st generation injectable
antipsychotic drug) and still later another course of Clozaril, Invega (another
2nd generation antipsychotic) and Zyprexia!
From
such a history of drug failures one might think a psychiatrist might consider
another path than biological treatments and taper all drugs to determine what
the patient is really like without the
drugs and any of their adverse side effects, which would be my
recommendation. Actually another
psychiatrist reviewed the medical record and advised a new path of addressing
psycho social factors in the patient’s life.
Actually the World Health Organization conducted two schizophrenia
treatment studies (see Reference) in European countries and the U.S. (primarily
drug therapy) vs. 3 third world countries (no drug therapy with schizophrenic
patients) and the latter had substantially better outcomes (including fewer
re-hospitalizations) than in the drug treated countries!
However, when Charles did not obviously respond to drug treatment the
decision was to turn to another biologic, ECT.
In view of the history of Charles’ treatment thus far I hope his treating
psychiatrist will not ask the court for an enforced
lobotomy!
From my
review of the health literature for my book I find that many psychiatric drugs
have little or no clinical effectives but these drugs also impair brain
functions (in some cases permanently with long term drug use) and when the brain
is impaired the patient’s learning
ability is also impaired!
Patients with depression, anxiety, PTSD, borderline personality and yes, even
schizophrenia, certainly need their ability to learn in their recovery.
Reference: World Health
Organization (WHO). “Schizophrenia:
an international follow up study”.
Chictrester. John
Wiley&Sons: 1997.
The
author’s new book is available at:
https://www.amazon.com/Whats-Wrong-U-S-Healthcare-how-ebook/dp/B08NKCZ24T/ref=pd_rhf_pe_p_img_3?_encoding=UTF8&psc=1&refRID=EJ5RM2G6Q46HMFQFXH80